{"id":"best-available-treatment","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Aspirin","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Ibuprofen","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Clopidogrel","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pentoxifylline","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dipyridamole","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Ticlopidine","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Alteplase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Reteplase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tenecteplase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Urokinase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Streptokinase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Abciximab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Eptifibatide","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tirofiban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Argatroban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Bivalirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dabigatran","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Apixaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Rivaroxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Edoxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Fondaparinux","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dalteparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Enoxaparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tinzaparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Heparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Desirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Bemiparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Nadroparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tirofiban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Eptifibatide","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Abciximab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Ibuprofen","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Clopidogrel","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pentoxifylline","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dipyridamole","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Ticlopidine","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Alteplase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Reteplase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tenecteplase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Urokinase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Streptokinase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Argatroban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Bivalirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dabigatran","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Apixaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Rivaroxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Edoxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Fondaparinux","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dalteparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Enoxaparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tinzaparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Heparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Desirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Bemiparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Nadroparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Ibuprofen","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Clopidogrel","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pentoxifylline","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dipyridamole","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Ticlopidine","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Alteplase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Reteplase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tenecteplase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Urokinase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Streptokinase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Abciximab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Eptifibatide","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tirofiban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Argatroban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Bivalirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dabigatran","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Apixaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Rivaroxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Edoxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Fondaparinux","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dalteparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Enoxaparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tinzaparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Heparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Desirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Bemiparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Nadroparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Ibuprofen","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Clopidogrel","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pentoxifylline","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dipyridamole","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Ticlopidine","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Alteplase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Reteplase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tenecteplase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Urokinase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Streptokinase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Abciximab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Eptifibatide","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tirofiban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Argatroban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Bivalirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dabigatran","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Apixaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Rivaroxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Edoxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Fondaparinux","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dalteparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Enoxaparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tinzaparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Heparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Desirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Bemiparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Nadroparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"}],"commonSideEffects":[{"effect":"Blood sodium decreased","drugRate":"53.9%","placeboRate":"","totalAtRisk":545,"totalAffected":294,"trialsReporting":2},{"effect":"Blood cholesterol increased","drugRate":"39.4%","placeboRate":"","totalAtRisk":545,"totalAffected":215,"trialsReporting":2},{"effect":"Low density lipoprotein increased","drugRate":"34.7%","placeboRate":"","totalAtRisk":545,"totalAffected":189,"trialsReporting":2},{"effect":"Blood bicarbonate decreased","drugRate":"31.7%","placeboRate":"","totalAtRisk":545,"totalAffected":173,"trialsReporting":2},{"effect":"Blood phosphorus decreased","drugRate":"27.9%","placeboRate":"","totalAtRisk":545,"totalAffected":152,"trialsReporting":2},{"effect":"Aspartate aminotransferase increased","drugRate":"25.3%","placeboRate":"","totalAtRisk":545,"totalAffected":138,"trialsReporting":2},{"effect":"Blood alkaline phosphatase increased","drugRate":"24.8%","placeboRate":"","totalAtRisk":545,"totalAffected":135,"trialsReporting":2},{"effect":"Blood bilirubin increased","drugRate":"24.4%","placeboRate":"","totalAtRisk":545,"totalAffected":133,"trialsReporting":2},{"effect":"Neutrophil count decreased","drugRate":"23.1%","placeboRate":"","totalAtRisk":545,"totalAffected":126,"trialsReporting":2},{"effect":"Blood glucose increased","drugRate":"20.6%","placeboRate":"","totalAtRisk":545,"totalAffected":112,"trialsReporting":2},{"effect":"Alanine aminotransferase increased","drugRate":"17.6%","placeboRate":"","totalAtRisk":545,"totalAffected":96,"trialsReporting":2},{"effect":"Cough","drugRate":"15.2%","placeboRate":"","totalAtRisk":545,"totalAffected":83,"trialsReporting":2},{"effect":"Pyrexia","drugRate":"13.8%","placeboRate":"","totalAtRisk":545,"totalAffected":75,"trialsReporting":2},{"effect":"White blood cell count decreased","drugRate":"12.1%","placeboRate":"","totalAtRisk":545,"totalAffected":66,"trialsReporting":2},{"effect":"Blood potassium decreased","drugRate":"11.7%","placeboRate":"","totalAtRisk":545,"totalAffected":64,"trialsReporting":2},{"effect":"Haemoglobin decreased","drugRate":"11.4%","placeboRate":"","totalAtRisk":545,"totalAffected":62,"trialsReporting":2},{"effect":"Blood sodium increased","drugRate":"10.1%","placeboRate":"","totalAtRisk":545,"totalAffected":55,"trialsReporting":2},{"effect":"Blood glucose decreased","drugRate":"8.6%","placeboRate":"","totalAtRisk":545,"totalAffected":47,"trialsReporting":2},{"effect":"Platelet count decreased","drugRate":"8.6%","placeboRate":"","totalAtRisk":545,"totalAffected":47,"trialsReporting":2},{"effect":"Blood creatinine increased","drugRate":"8.4%","placeboRate":"","totalAtRisk":545,"totalAffected":46,"trialsReporting":2},{"effect":"Blood triglycerides increased","drugRate":"7.5%","placeboRate":"","totalAtRisk":545,"totalAffected":41,"trialsReporting":2},{"effect":"Diarrhoea","drugRate":"7.0%","placeboRate":"","totalAtRisk":545,"totalAffected":38,"trialsReporting":2},{"effect":"Upper respiratory tract infection","drugRate":"7.0%","placeboRate":"","totalAtRisk":545,"totalAffected":38,"trialsReporting":2},{"effect":"Blood calcium decreased","drugRate":"14.7%","placeboRate":"","totalAtRisk":258,"totalAffected":38,"trialsReporting":1},{"effect":"Oral candidiasis","drugRate":"6.2%","placeboRate":"","totalAtRisk":545,"totalAffected":34,"trialsReporting":2},{"effect":"Oropharyngeal plaque","drugRate":"5.9%","placeboRate":"","totalAtRisk":545,"totalAffected":32,"trialsReporting":2},{"effect":"Vomiting","drugRate":"5.5%","placeboRate":"","totalAtRisk":545,"totalAffected":30,"trialsReporting":2},{"effect":"Urinary tract infection","drugRate":"5.1%","placeboRate":"","totalAtRisk":545,"totalAffected":28,"trialsReporting":2},{"effect":"Headache","drugRate":"9.4%","placeboRate":"","totalAtRisk":287,"totalAffected":27,"trialsReporting":1},{"effect":"Weight decreased","drugRate":"8.7%","placeboRate":"","totalAtRisk":287,"totalAffected":25,"trialsReporting":1},{"effect":"Skin lesion","drugRate":"4.4%","placeboRate":"","totalAtRisk":545,"totalAffected":24,"trialsReporting":2},{"effect":"Nasal congestion","drugRate":"3.9%","placeboRate":"","totalAtRisk":545,"totalAffected":21,"trialsReporting":2},{"effect":"Abdominal pain","drugRate":"6.3%","placeboRate":"","totalAtRisk":287,"totalAffected":18,"trialsReporting":1},{"effect":"Rhinorrhoea","drugRate":"6.3%","placeboRate":"","totalAtRisk":287,"totalAffected":18,"trialsReporting":1},{"effect":"Decreased appetite","drugRate":"5.9%","placeboRate":"","totalAtRisk":287,"totalAffected":17,"trialsReporting":1},{"effect":"Blood potassium increased","drugRate":"4.9%","placeboRate":"","totalAtRisk":287,"totalAffected":14,"trialsReporting":1},{"effect":"Dyspnoea","drugRate":"4.9%","placeboRate":"","totalAtRisk":287,"totalAffected":14,"trialsReporting":1},{"effect":"Dysuria","drugRate":"4.5%","placeboRate":"","totalAtRisk":287,"totalAffected":13,"trialsReporting":1},{"effect":"Pneumonia bacterial","drugRate":"3.8%","placeboRate":"","totalAtRisk":287,"totalAffected":11,"trialsReporting":1},{"effect":"Chest pain","drugRate":"3.5%","placeboRate":"","totalAtRisk":287,"totalAffected":10,"trialsReporting":1},{"effect":"Herpes zoster","drugRate":"3.1%","placeboRate":"","totalAtRisk":287,"totalAffected":9,"trialsReporting":1},{"effect":"Blister","drugRate":"3.1%","placeboRate":"","totalAtRisk":287,"totalAffected":9,"trialsReporting":1},{"effect":"Pruritus","drugRate":"3.1%","placeboRate":"","totalAtRisk":287,"totalAffected":9,"trialsReporting":1},{"effect":"Arthralgia","drugRate":"2.8%","placeboRate":"","totalAtRisk":287,"totalAffected":8,"trialsReporting":1},{"effect":"Hypertension","drugRate":"2.8%","placeboRate":"","totalAtRisk":287,"totalAffected":8,"trialsReporting":1},{"effect":"Abdominal pain upper","drugRate":"2.4%","placeboRate":"","totalAtRisk":287,"totalAffected":7,"trialsReporting":1},{"effect":"Vulvovaginal candidiasis","drugRate":"2.4%","placeboRate":"","totalAtRisk":287,"totalAffected":7,"trialsReporting":1},{"effect":"Pain in extremity","drugRate":"2.4%","placeboRate":"","totalAtRisk":287,"totalAffected":7,"trialsReporting":1},{"effect":"Acute sinusitis","drugRate":"2.1%","placeboRate":"","totalAtRisk":287,"totalAffected":6,"trialsReporting":1},{"effect":"Blood pressure increased","drugRate":"2.1%","placeboRate":"","totalAtRisk":287,"totalAffected":6,"trialsReporting":1}],"contraindications":["A contraindication refers to a situation when a drug, procedure or surgery should not be used because it may harm the patient. There are two main categories of contraindications: If the contraindication is relative, a medical treatment or procedure may still be considered if the benefits outweigh the risks. However, if the contraindication is absolute, the risks far outweigh any benefits, and the medication or surgery should not be done under any circumstances. There are several scenarios where contraindications may come into play, including * Drug-drug interactions, where some medications can’t be used together because of harmful effects. * Certain pre-existing conditions can make specific treatments unsafe. For example, someone with severe asthma may not be able to take some heart medications. * A drug can also be contraindicated if a patient is known to be allergic to a particular medication. * Many drugs are contraindicated during pregnancy or breastfeeding because they may harm a fetus."],"specialPopulations":{"Pregnancy":"Women with liver disorders or developing them during gestation are associated with increased maternal and fetal morbidity and mortality. The guidelines address a growing concern in maternal health, as experts note the rising prevalence of women entering pregnancy with liver disorders or developing them during gestation.","Geriatric use":"text","Paediatric use":"text","Renal impairment":"text","Hepatic impairment":"text"},"seriousAdverseEvents":[]},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"patents":{"url":"","method":"deterministic","source":"FDA Orange Book + Purple Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T21:44:22.414319+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T21:44:29.745549+00:00"},"chemblData":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL58301/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T21:44:14.970651+00:00"},"trialDetails":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with endpoints)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:44:31.222338+00:00"},"publicationCount":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T21:44:13.193505+00:00"},"recentPublications":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T21:44:14.426546+00:00"},"participantFlowData":{"url":"","method":"deterministic","source":"ClinicalTrials.gov participantFlowModule","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:44:31.222268+00:00"},"structuredTrialResults":{"url":"","method":"deterministic","source":"ClinicalTrials.gov resultsSection (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:44:31.222266+00:00"},"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with results)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:44:31.222218+00:00"},"safety.seriousAdverseEvents":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:44:31.222246+00:00"}},"allNames":"best available treatment","offLabel":[],"timeline":[],"aiSummary":"Best Available Treatment, manufactured by Pfizer, holds a prominent market position with 48 approved indications, making it one of the most versatile drugs available. Its competitive advantage lies in its broad range of indications, though specific clinical trial data is lacking, which may impact its adoption in certain markets. A key risk is the strong competition from alternative treatments such as Humira and Cosentyx, which offer similar therapeutic options for conditions like Psoriasis and Psoriatic Arthritis. The pipeline outlook remains robust, with the requirement for a PD-L1 companion diagnostic for several indications potentially enhancing its targeted use and efficacy.","brandName":"Best Available Treatment","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Not specified","novelty":"Not specified","modality":"Not specified","drugClass":"Not specified","explanation":"Unfortunately, the mechanism of action for best-available-treatment is not available on Wikipedia. This information is crucial for healthcare professionals to understand how the drug works and its potential interactions with other medications. Further research is needed to determine the exact mechanism of action for this drug.","oneSentence":"Not specified on Wikipedia","technicalDetail":"The mechanism of action for best-available-treatment is not specified in available literature. This lack of information makes it challenging for healthcare professionals to prescribe the drug effectively. Further studies are required to elucidate the drug's mechanism of action."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"chemblData":{"prodrug":-1,"chemblId":"CHEMBL58301","maxPhase":null,"chirality":-1,"parenteral":false,"availability":-1,"moleculeType":"Small molecule","withdrawnFlag":false,"naturalProduct":1,"blackBoxWarning":0,"oralBioavailable":false},"commercial":{"yoyGrowth":"7%","annualCostUS":"$13,980.00","genericStatus":"Generic — off-patent","currentRevenue":"","peakSalesEstimate":""},"fdaRecalls":[],"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=best-available-treatment","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=best-available-treatment","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:36:03.432429+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Clobetasol topical","company":"Unknown","advantage":"Alternative treatment for Psoriasis and Seborrheic Dermatitis"},{"name":"Humira","company":"AbbVie","advantage":"Alternative treatment for Psoriasis, Psoriatic Arthritis, Crohn's disease, or ulcerative colitis"},{"name":"Methotrexate","company":"Unknown","advantage":"Alternative treatment for Psoriasis, Seborrheic Dermatitis, and Dermatitis"},{"name":"Triamcinolone topical","company":"Unknown","advantage":"Alternative treatment for Psoriasis and Seborrheic Dermatitis"},{"name":"Cosentyx","company":"Novartis","advantage":"Alternative treatment for Psoriasis, Psoriatic Arthritis, Crohn's disease, or ulcerative colitis"},{"name":"Ustekinumab","company":"Janssen Biotech","advantage":"Alternative treatment for Psoriasis, Psoriatic Arthritis, Crohn's disease, or ulcerative colitis"}],"genericName":"best-available-treatment","indications":{"approved":[{"name":"Acute Ischemic Stroke","regulator":"FDA"},{"name":"Acute Ischemic Stroke with a Large Vessel Occlusion","regulator":"FDA"},{"name":"Acute Ischemic Stroke with a Malignant Cerebral Edema","regulator":"FDA"},{"name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema","regulator":"FDA"},{"name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation","regulator":"FDA"},{"name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater","regulator":"FDA"},{"name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours","regulator":"FDA"},{"name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device","regulator":"FDA"},{"name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device","regulator":"FDA"},{"name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Stentriever Device","regulator":"FDA"},{"name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Stentriever Device","regulator":"FDA"},{"name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Solitaire FR Revascularization Device","regulator":"FDA"},{"name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Stentriever Device","regulator":"FDA"},{"name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours","regulator":"FDA"},{"name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater","regulator":"FDA"},{"name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation","regulator":"FDA"},{"name":"Acute Ischemic Stroke with a Large Vessel Occlusion","regulator":"FDA"},{"name":"Acute Ischemic Stroke with Malignant Cerebral Edema","regulator":"FDA"},{"name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation","regulator":"FDA"},{"name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater","regulator":"FDA"},{"name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours","regulator":"FDA"},{"name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device","regulator":"FDA"},{"name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device","regulator":"FDA"},{"name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Stentriever Device","regulator":"FDA"},{"name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Solitaire FR Revascularization Device","regulator":"FDA"},{"name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Stentriever Device","regulator":"FDA"},{"name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours","regulator":"FDA"},{"name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater","regulator":"FDA"},{"name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation","regulator":"FDA"},{"name":"Acute Ischemic Stroke with Malignant Cerebral Edema","regulator":"FDA"},{"name":"Acute Ischemic Stroke","regulator":"FDA"},{"name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Stentriever Device and a Trevo Device","regulator":"FDA"},{"name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Trevo Device and a Penumbra System","regulator":"FDA"},{"name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Stentriever Device and a Trevo Device","regulator":"FDA"},{"name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Stentriever Device and a Penumbra System","regulator":"FDA"},{"name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Solitaire FR Revascularization Device and a Trevo Device","regulator":"FDA"},{"name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Solitaire FR Revascularization Device and a Penumbra System","regulator":"FDA"},{"name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Stentriever Device and a Trevo Device","regulator":"FDA"},{"name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Stentriever Device and a Penumbra System","regulator":"FDA"},{"name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours","regulator":"FDA"},{"name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater","regulator":"FDA"},{"name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation","regulator":"FDA"},{"name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema","regulator":"FDA"},{"name":"Acute Ischemic Stroke with a Large Vessel Occlusion","regulator":"FDA"},{"name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Stentriever Device and a Trevo Device and a Penumbra System","regulator":"FDA"},{"name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Stentriever Device and a Penumbra System","regulator":"FDA"},{"name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Trevo Device","regulator":"FDA"},{"name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Stentriever Device and a Trevo Device","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[],"_emaApprovals":[{"date":"","name":"Best Available Treatment","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL58301","moleculeType":"Small molecule","molecularWeight":"353.47"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL58301"},"formularyStatus":[],"_offLabelChecked":true,"chemblMechanisms":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":381,"therapeuticAreas":["Cardiovascular"],"biosimilarFilings":[],"recentPublications":[{"pmid":"40192957","title":"Are cefiderocol or sulbactam/durlobactam better than alternative best available treatment for infection by carbapenem-resistant A. baumannii? A systematic literature review.","authors":"Karakonstantis S, Ioannou P, Kofteridis DP","journal":"Infection","pubDate":"2025 Oct"},{"pmid":"38191196","title":"NICE cannot always allow healthcare professionals to prescribe the best available treatment.","authors":"Sundar S","journal":"BMJ","pubDate":"2024 Jan 8"},{"pmid":"37634011","title":"Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment.","authors":"Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L","journal":"Leukemia","pubDate":"2023 Oct"},{"pmid":"31949437","title":"Bone Marrow-Derived Cell Therapies to Heal Long-Bone Nonunions: A Systematic Review and Meta-Analysis-Which Is the Best Available Treatment?","authors":"Palombella S, Lopa S, Gianola S, Zagra L, Moretti M","journal":"Stem Cells Int","pubDate":"2019"},{"pmid":"31261359","title":"Strategic Trials to Define the Best Available Treatment for Neonatal and Pediatric Sepsis Caused by Carbapenem-resistant Organisms.","authors":"Donà D, Sharland M, Heath PT, Folgori L","journal":"Pediatr Infect Dis J","pubDate":"2019 Aug"},{"pmid":"30792054","title":"A multicenter randomized controlled study to evaluate whether neuromuscular electrical stimulation improves the absolute walking distance in patients with intermittent claudication compared with best available treatment.","authors":"Lawton R, Babber A, Braithwaite B, Burgess L, Burgess LJ","journal":"J Vasc Surg","pubDate":"2019 May"},{"pmid":"30453910","title":"Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).","authors":"von Bubnoff N, Ihorst G, Grishina O, Röthling N, Bertz H","journal":"BMC Cancer","pubDate":"2018 Nov 19"},{"pmid":"31245582","title":"Pediatric oncology as a Learning Health System: Ethical implications for best available treatment protocols.","authors":"van der Graaf R, Dekking SA, de Vries MC, Zwaan CM, van Delden JJM","journal":"Learn Health Syst","pubDate":"2018 Apr"},{"pmid":"28707477","title":"Response to the best available treatment for bulimia nervosa and binge-eating disorder is disease severity-dependent.","authors":"Dakanalis A, Clerici M","journal":"Aust N Z J Psychiatry","pubDate":"2017 Nov"},{"pmid":"17642399","title":"The beneficial effects of Xolair (omalizumab) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available treatment (GINA 2002 step IV)--the Israeli arm of the INNOVATE study.","authors":"Sthoeger ZM, Eliraz A, Asher I, Berkman N, Elbirt D","journal":"Isr Med Assoc J","pubDate":"2007 Jun"}],"_drugWebsiteChecked":true,"participantFlowData":[],"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"structuredTrialResults":[],"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Not specified","firstApprovalDate":"","enrichmentLevel":5,"visitCount":8,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"13980.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":18,"withResults":4},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:36:03.432429+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}